Medexus Pharmaceuticals Inkomsten in het verleden
Verleden criteriumcontroles 1/6
Medexus Pharmaceuticals has been growing earnings at an average annual rate of 30.8%, while the Pharmaceuticals industry saw earnings growing at 46% annually. Revenues have been growing at an average rate of 18.7% per year. Medexus Pharmaceuticals's return on equity is 3.4%, and it has net margins of 1%.
Belangrijke informatie
30.8%
Groei van de winst
33.7%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 23.1% |
Inkomstengroei | 18.7% |
Rendement op eigen vermogen | 3.4% |
Nettomarge | 1.0% |
Volgende winstupdate | 07 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings
Aug 19Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 10Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth
Jul 31The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet
Jun 15Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden
Apr 25Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive
Mar 03Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story
Jan 06Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors
Oct 11Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Sep 11Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky
Jan 19Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Sep 22Is Medexus Pharmaceuticals (TSE:MDP) Weighed On By Its Debt Load?
Dec 16Medexus Pharmaceuticals Inc. (TSE:MDP) Analysts Just Cut Their EPS Forecasts Substantially
Aug 21Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Aug 04Opbrengsten en kosten
Hoe Medexus Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 109 | 1 | 43 | 1 |
31 Mar 24 | 113 | 0 | 45 | 2 |
31 Dec 23 | 116 | 6 | 46 | 2 |
30 Sep 23 | 119 | 5 | 47 | 3 |
30 Jun 23 | 117 | 3 | 48 | 3 |
31 Mar 23 | 108 | 1 | 48 | 3 |
31 Dec 22 | 100 | -11 | 47 | 3 |
30 Sep 22 | 92 | -11 | 46 | 3 |
30 Jun 22 | 82 | 2 | 44 | 4 |
31 Mar 22 | 77 | -3 | 44 | 6 |
31 Dec 21 | 74 | -8 | 44 | 7 |
30 Sep 21 | 77 | -20 | 43 | 7 |
30 Jun 21 | 77 | -31 | 40 | 6 |
31 Mar 21 | 80 | -28 | 36 | 5 |
31 Dec 20 | 79 | -19 | 33 | 3 |
30 Sep 20 | 69 | -9 | 31 | 2 |
30 Jun 20 | 64 | -7 | 31 | 2 |
31 Mar 20 | 56 | -5 | 31 | 1 |
31 Dec 19 | 47 | -4 | 31 | 1 |
30 Sep 19 | 45 | -3 | 29 | 0 |
30 Jun 19 | 36 | -6 | 22 | 0 |
31 Mar 19 | 25 | -5 | 16 | 0 |
31 Dec 18 | 17 | -5 | 10 | 0 |
30 Sep 18 | 9 | -5 | 6 | 0 |
30 Jun 18 | 8 | -2 | 6 | 0 |
31 Mar 18 | 8 | -3 | 6 | 0 |
31 Dec 17 | 8 | -3 | 6 | 0 |
30 Sep 17 | 7 | -3 | 6 | 0 |
30 Jun 17 | 6 | -3 | 6 | 0 |
31 Mar 17 | 5 | -1 | 5 | 0 |
31 Dec 16 | 4 | 1 | 5 | 0 |
30 Sep 16 | 3 | 1 | 5 | 0 |
30 Jun 16 | 3 | 1 | 5 | 0 |
31 Mar 16 | 3 | -2 | 5 | 0 |
31 Dec 15 | 3 | -4 | 5 | 0 |
30 Sep 15 | 2 | -4 | 5 | 0 |
30 Jun 15 | 2 | -5 | 6 | 0 |
31 Mar 15 | 2 | -4 | 6 | 0 |
31 Dec 14 | 3 | -4 | 6 | 0 |
30 Sep 14 | 3 | -4 | 5 | 0 |
30 Jun 14 | 4 | -3 | 5 | 0 |
31 Mar 14 | 3 | -3 | 5 | 0 |
31 Dec 13 | 4 | -2 | 4 | 0 |
Kwaliteitswinsten: MDP has a large one-off loss of $2.3M impacting its last 12 months of financial results to 30th June, 2024.
Groeiende winstmarge: MDP's current net profit margins (1%) are lower than last year (2.8%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: MDP has become profitable over the past 5 years, growing earnings by 30.8% per year.
Versnelling van de groei: MDP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: MDP had negative earnings growth (-66.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-40.8%).
Rendement op eigen vermogen
Hoge ROE: MDP's Return on Equity (3.4%) is considered low.